Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
Stock Information for Soligenix Inc.
Loading
Please wait while we load your information from QuoteMedia.